Risk stratification of patients with pulmonary embolism based on pulse rate and D-dimer concentration

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 683-687

  Agterof, Mariette J ^a   Van Bladel, Esther R ^a   Schutgens, Roger E G ^b   Snijder, Repke J ^c   Tromp, Ellen A M ^c   Prins, Martin H ^d   Biesma, Douwe H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Outcome; Prediction model; Pulmonary embolism; Risk; Serious adverse events

Indexed keywords

D DIMER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FIBRIN; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 70449474095     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-04-0229     Document Type: Article

References (26)

1. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: Part II Risk stratification, treatment and prevention. Circulation 2003; 108: 2834-2838. (Pubitemid 37517808)
2. Tapson VF, Witty LA. Massive pulmonary embolism: diagnostic and therapeutic strategies. Clin Chest Med 1995; 16: 329-340.
3. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-28S. (Pubitemid 39297960)
4. Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular- weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809-1812. (Pubitemid 28421425)
5. Kovacs MJ, Anderson D, Morrow B et al. Out-patient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000; 83: 209-211. (Pubitemid 30093220)
6. Wells PS, Anderson DR, Rodger MA et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep venous thrombosis and pulmonary embolism. Arch Intern Med 2005; 165: 733-738.
7. Aujesky D, Smith KJ, Cornuz J et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005; 128: 1601-1610. (Pubitemid 41324453)
8. Aujesky D, Obrosky DS, Stone RA et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med 2006; 166: 169-175. (Pubitemid 43144939)
9. Wicki J, Perrier A, Perneger TV et al. Predicting adverse outcome in patients with acute pulmonary embolism: A risk score. Thromb Haemost 2000; 84: 548-552. (Pubitemid 30798931)
10. Klok FA, Djurabi RK, Nijkeuter M et al. High D-dimer level is associated with increased 15-d and 3 months mortality through a more central localization of pulmonary emboli and serious comorbidity. Br J Haematol 2008; 140: 218-222. (Pubitemid 350265038)
11. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389. (Pubitemid 29192409)
12. Laporte S, Mismetti P, Décousus H et al. Clinical Predictors for fatal pulmonary embolism in 15520 patients with venous thromboembolism. Circulation 2008; 117: 1711-1716.
13. Nijkeuter M, Söhne M, Tick LW et al. The natural course of hemodynamically stable pulmonary embolism. Clinical outcome and risk factors in a large prospective cohort study. Chest 2007; 131: 517-523.
14. Nendaz MR, Bandelier P, Aujesky D, et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 2004; 91: 1232-1236. (Pubitemid 38821282)
15. Konstantinides S, Geibel A, Olschewski M et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Results of a multicenter registry. Circulation 1997; 96: 882-888.
16. The Columbus Investigators. Low-molecularweight heparin in the treatment of patients with venous tromboembolism. N Engl J Med 1997; 337: 657-662. (Pubitemid 27375471)
17. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669. (Pubitemid 27375472)
18. Caprini JA, Tapson VF, Hyers TM et al. Treatment of venous tromboembolism: Adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005; 42: 726-733.
19. Panis LJ, Kolbach DN, Hamulyák K et al. Identifying inappropriate hospital stay in patients with venous thromboembolism. Eur J Intern Med 2004; 15: 39-44. (Pubitemid 38453041)
20. van der Meer RW, Pattynama PM, van Strijen MJ et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005; 235: 798-803.
21. Goldhaber SZ. Assessing the prognosis of acute pulmonary embolism: Tricks of the trade. Chest 2008; 133: 334-336. (Pubitemid 351272386)
22. Aujesky D, Roy PM, Guy M et al. Prognostic value of D-dimer in patients with pulmonary embolism. Thromb Haemost 2006; 96: 478-482. (Pubitemid 44560682)
23. Paneesha S, Cheyne E, French K et al. High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcome. Br J Haematol 2006; 135: 85-90. (Pubitemid 44337667)
24. Schutgens REG, Beckers MMJ, Haas JLM et al. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90: 214-219.
25. Gaffney PJ, Creighton LJ, Callus MJ et al. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). II Evolution in a variety of clinical conditions. Br J Haematol 1988; 68: 91-96. (Pubitemid 18051947)
26. Schutgens REG, Haas FJ, Biesma DH. Reduced efficacy of clinical probability score and D-dimer assay in eldery subjects suspecting of having deep vein thrombosis. Br J Haematol 2005; 129: 653-657.